<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335864</url>
  </required_header>
  <id_info>
    <org_study_id>Hydrosalpinx and ICSI</org_study_id>
    <nct_id>NCT04335864</nct_id>
  </id_info>
  <brief_title>Comparing the Impact of 2 Different Techniques in Management of Hydrosalpinx on Pregnancy Rates Following ICSI</brief_title>
  <official_title>A Clinical Trial Comparing Laparoscopic Salpingectomy Versus Hysteroscopic Proximal Tubal Occlusion on Pregnancy Rates Following ICSI (Intra-Cytoplasmic Sperm Injection) in Infertile Cases of Hydrosalpinx.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment and comparing pregnancy outcomes in hydrosalpinx patients treated by hysteroscopic&#xD;
      tubal occlusion and laparoscopic salpingectomy before ICSI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydrosalpinx has a detrimental effect on the rates of implantation, pregnancy and early&#xD;
      pregnancy loss following IVF. A meta-analysis demonstrated that the implantation rate and&#xD;
      clinical pregnancy rate decreased by 50% in patients with hydrosalpinx. The negative&#xD;
      consequences could be due to embryotoxic properties, a decrease in endometrial receptivity,&#xD;
      and hydrosalpinx fluid mechanically flushing the embryo from the uterus.&#xD;
&#xD;
      Although laparoscopic salpingectomy and laparoscopic proximal ligation increase ongoing&#xD;
      pregnancy rates in women with hydrosalpinges, those interventions are invasive and carry&#xD;
      anaesthetic and surgical risks, especially in the presence of extensive adhesions, often seen&#xD;
      in women with hydrosalpinges. In view of the possible adverse effects of laparoscopic&#xD;
      surgery, an alternative less-invasive treatment for hydrosalpinges prior to IVF would be&#xD;
      useful.&#xD;
&#xD;
      The effectiveness of hysteroscopic tubal occlusion when compared with salpingectomy has not&#xD;
      been established. Randomized clinical trials comparing both procedures prior to IVF are&#xD;
      lacking.&#xD;
&#xD;
      The present study was designed to compare hysteroscopic tubal occlusion and laparoscopic&#xD;
      salpingectomy in the treatment of hydrosalpinges prior to IVF.&#xD;
&#xD;
      This study hypothesized that in women scheduled for IVF/ICSI hysteroscopic proximal occlusion&#xD;
      of hydrosalpinges would be non-inferior to laparoscopic salpingectomy in terms of ongoing&#xD;
      pregnancy rates following IVF/ICSI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate following ICSI</measure>
    <time_frame>14 days after Embryo transfer</time_frame>
    <description>Defined as positive qualitative bhcg(beta human chorionic gonadotropin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy following ICSI</measure>
    <time_frame>8 weeks after Embryo transfer</time_frame>
    <description>Defined as positive fetal heart rate on ultrasound at 8weeks gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Hydrosalpinx</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>39 patients with hydrosalpinx will have laparoscopic salpingectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic salpingectomy</intervention_name>
    <description>39 patients with hydrosalpinx will have laparoscopic salpingectomy</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hystroscopic proximal tubal occlusion</intervention_name>
    <description>39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary or secondary infertility cases&#xD;
&#xD;
          -  unilateral or bilateral hydrosalpinx proved by HSG (hystersalpingogram) or by&#xD;
             TVUS(transvaginal ultrasound) .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uterine factor of infertility&#xD;
&#xD;
          -  male factor of infertility&#xD;
&#xD;
          -  preexisting ovarian pathology&#xD;
&#xD;
          -  Presence of septic focus&#xD;
&#xD;
          -  medical or surgical conditions that contraindicated pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kasr Alainy hospital-cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Shaimaa Mostafa Mohammed Refaay El shemy</investigator_full_name>
    <investigator_title>Principal investigator, Lecturer in obstetrics and gyneocolgy department, Cairo university</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

